Eyeforpharma market access and pricing excellence conference review 2015

A solution to the current funding crisis for budget-busting breakthrough treatments has been proposed by Soeren Mattke, senior scientist at the RAND Corporation think tank, involving payers and governments borrowing from pharma. However, multiple obstacles would need to be overcome for such innovative funding schemes to work in practice, and it can only be expected that they will be used in a handful of cases.

Spotlight

Vel Vaccines Biosciences

VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.

OTHER WHITEPAPERS
news image

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More
news image

Sales coaching: preparing for the new reality in pharma

whitePaper | October 14, 2022

COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment.

Read More
news image

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Read More
news image

Adapting to Pharma’s Next Normal

whitePaper | October 4, 2022

Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

Spotlight

Vel Vaccines Biosciences

VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.

Events